OCATA THERAPEUTICS INC COM STK (OCAT1)

Sector:
HEALTH CARE
Industry:
HEALTH CARE
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Paul K. Wotton
Employees:
37
33 LOCKE DRIVE, MARLBOROUGH, MA 01752
508-756-1212

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Ocata Therapeutics, Inc., a clinical stage biotechnology company, develops and commercializes regenerative ophthalmology therapeutics in the United States.

Data derived from most recent annual or quarterly report
Market Cap 358.281 Million Shares Outstanding42.3 Million Avg 30-day Volume 676.696 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.49
Price to Revenue872.48 Debt to Equity0.4387 EBITDA-24.544 Million
Price to Book Value12.8491 Operating Margin-13801.420100000001 Enterprise Value150.715 Million
Current Ratio6.986 EPS Growth0.69 Quick Ratio6.898
1 Yr BETA -3.0701 52-week High/Low 0.0 / Profit Margin-12312.2294
Operating Cash Flow Growth-14.3178 Altman Z-Score-11.429 Free Cash Flow to Firm -14.329 Million
View SEC Filings from OCAT1 instead.

View recent insider trading info

Funds Holding OCAT1 (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding OCAT1 BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

SHAPIRO ALAN C

  • Director
No longer subject to file 2016-02-10 0

PERRY GREGORY D

  • Director
No longer subject to file 2016-02-10 0

LANGER ROBERT

  • Director
No longer subject to file 2016-02-10 0

LEVY BRIAN

  • Director
No longer subject to file 2016-02-10 0

LOSHITZER ZOHAR

  • Director
No longer subject to file 2016-02-10 0

WOTTON PAUL K PRESIDENT AND CEO

  • Officer
  • Director
No longer subject to file 2016-02-10 0

JOOSTE H LE ROUX SVP OF BUS DEVELOPMENT & CCO

  • Officer
No longer subject to file 2016-02-10 0

LANZA ROBERT CHIEF SCIENTIFIC OFFICER

  • Officer
No longer subject to file 2016-02-10 0

MYLES EDWARD H COO & CFO

  • Officer
No longer subject to file 2016-02-10 0

HEFFERNAN MICHAEL THOMAS

  • Director
No longer subject to file 2016-02-10 0

ANGLADE EDDY CHIEF MEDICAL OFFICER

  • Officer
No longer subject to file 2016-02-10 0

RABIN GARY H CHAIRMAN & CFO

  • Officer
  • Director
14,262,401 2012-06-29 0

RUOSLAHTI ERKKI

  • Director
2,744,119 2011-03-04 0

CALDWELL WILLIAM M CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
  • 10% Owner
89,280,595 2009-11-13 0

WOLKIND IVAN SVP, CHIEF ACCOUNTING OFFICER

  • Officer
0 2008-02-06 0

DINSMORE JONATHAN SVP, CLINICAL & REGULATORY

  • Officer
0 2008-02-06 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments